85 related articles for article (PubMed ID: 816684)
21. Control methods and thresholds of acceptability for antibrucella vaccines.
Bosseray N
Dev Biol Stand; 1992; 79():121-8. PubMed ID: 1286747
[TBL] [Abstract][Full Text] [Related]
22. [Isolation of Brucella melitensis from ejaculate culture of a brucellosis patient with epididymoorchitis].
Sözen EE; Aksoy F; Aydin K; Köksal I; Yilmaz G; Aksoy HZ
Mikrobiyol Bul; 2007 Jul; 41(3):465-8. PubMed ID: 17933260
[TBL] [Abstract][Full Text] [Related]
23. A bile salt hydrolase of Brucella abortus contributes to the establishment of a successful infection through the oral route in mice.
Delpino MV; Marchesini MI; Estein SM; Comerci DJ; Cassataro J; Fossati CA; Baldi PC
Infect Immun; 2007 Jan; 75(1):299-305. PubMed ID: 17088355
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic antibody dependent cells in mice experimentally infected with Brucella abortus.
Galdiero F; Romano Carratelli C; Nuzzo I; Folgore A
Microbiologica; 1985 Jul; 8(3):217-24. PubMed ID: 3929026
[TBL] [Abstract][Full Text] [Related]
25. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
[TBL] [Abstract][Full Text] [Related]
26. Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen.
Phillips M; Deyoe BL; Canning PC
Am J Vet Res; 1989 Dec; 50(12):2158-61. PubMed ID: 2481994
[TBL] [Abstract][Full Text] [Related]
27. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
[TBL] [Abstract][Full Text] [Related]
28. Failure of ciprofloxacin to eradicate brucellosis in experimental animals.
al-Orainey IO; Bashandi AM; Saeed EN
J Chemother; 1990 Dec; 2(6):380-3. PubMed ID: 2093110
[TBL] [Abstract][Full Text] [Related]
29. An aerosolized Brucella spp. challenge model for laboratory animals.
Olsen SC; Waters WR; Stoffregen WS
Zoonoses Public Health; 2007; 54(8):281-5. PubMed ID: 17894637
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary study of two inbred mice models for infection and immunity of Brucellosis].
Zhang JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Feb; 11(1):18-24. PubMed ID: 2527626
[TBL] [Abstract][Full Text] [Related]
31. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
32. [Phenol-insoluble vaccine against human brucellosis: evaluation of the immunogenic power in guinea pigs].
Bolpe J; de Lapenta DF; García-Carrillo C
Rev Inst Med Trop Sao Paulo; 1991; 33(1):23-7. PubMed ID: 1843392
[TBL] [Abstract][Full Text] [Related]
33. [A comparative therapeutic and multicenter trial of rifampicin and doxycycline versus streptomycin and doxycycline in human brucellosis].
Solera J; Medrano F; Rodríguez M; Geijo P; Paulino J
Med Clin (Barc); 1991 May; 96(17):649-53. PubMed ID: 1905372
[TBL] [Abstract][Full Text] [Related]
34. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
[TBL] [Abstract][Full Text] [Related]
35. Immunity to Brucella abortus induced in mice by popliteal lymph node restricted strain 19 vaccination.
Plommet M; Plommet AM
Ann Rech Vet; 1989; 20(1):73-81. PubMed ID: 2494933
[TBL] [Abstract][Full Text] [Related]
36. Macrophages and Brucella.
Baldwin CL; Winter AJ
Immunol Ser; 1994; 60():363-80. PubMed ID: 8251581
[TBL] [Abstract][Full Text] [Related]
37. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes.
Prior S; Gander B; Lecároz C; Irache JM; Gamazo C
J Antimicrob Chemother; 2004 Jun; 53(6):981-8. PubMed ID: 15102748
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin.
Hernández-Caselles T; Vera A; Crespo F; Villalaín J; Gómez-Fernández JC
Am J Vet Res; 1989 Sep; 50(9):1486-8. PubMed ID: 2802318
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Brucella canis and Brucella abortus in vitro and in vivo by stable plurilamellar vesicle-encapsulated aminoglycosides.
Fountain MW; Weiss SJ; Fountain AG; Shen A; Lenk RP
J Infect Dis; 1985 Sep; 152(3):529-35. PubMed ID: 2411828
[TBL] [Abstract][Full Text] [Related]
40. Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis.
Sezak N; Kuruuzum Z; Cakir N; Yuce A
J Chemother; 2008 Feb; 20(1):58-62. PubMed ID: 18343745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
